Inventor · disambiguated record
Iain Lingard
Also filed as: LINGARD IAIN
20 granted patents·5 pending applications·60 citations·filing 2006–2022
93Inventor score
Files withBOEHRINGER INGELHEIM INT8AMGEN INC4CENTREXION THERAPEUTICS CORP3GIOVANNINI RICCARDO3BICYCLE TX LTD2
Top patents by PatentIndex Score
25 records- 0187US12448396B2Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitorsAMGEN INC·Filed 2022·Granted Oct 21, 2025·1 cites·59 claims
- 0286US10640486B2Heteroarylcarboxamide derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2016·Granted May 5, 2020·4 cites·13 claims
- 0386US9789082B2Somatostatin receptor subtype 4 (SSTR4) agonistsCENTREXION THERAPEUTICS CORP·Filed 2016·Granted Oct 17, 2017·5 cites·38 claims
- 0485US10675268B2Somatostatin receptor subtype 4 (SSTR4) agonistsCENTREXION THERAPEUTICS CORP·Filed 2018·Granted Jun 9, 2020·2 cites·15 claims
- 0585US10166214B2Somatostatin receptor subtype 4 (SSTR4) agonistsCENTREXION THERAPEUTICS CORP·Filed 2017·Granted Jan 1, 2019·4 cites·25 claims
- 0685US8642585B2Indanyloxydihydrobenzofuranylacetic acidsECKHARDT MATTHIAS·Filed 2013·Granted Feb 4, 2014·9 cites·32 claims
- 0785US8633182B2Indanyloxyphenylcyclopropanecarboxylic acidsHAMPRECHT DIETER·Filed 2013·Granted Jan 21, 2014·11 cites·17 claims
- 0883US10501440B2Heteroarylcarboxamide derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2018·Granted Dec 10, 2019·4 cites·14 claims
- 0983US9371282B2Somatostatin receptor subtype 4 (SSTR4) agonistsCT XION THERAPEUTICS CORP·Filed 2014·Granted Jun 21, 2016·8 cites·48 claims
- 1082US10399961B2Heteroarylcarboxamide derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2016·Granted Sep 3, 2019·4 cites·12 claims
- 1178US10071974B2Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonistsBOEHRINGER INGELHEIM INT·Filed 2015·Granted Sep 11, 2018·2 cites·25 claims
- 1276US10183940B2Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonistsBOEHRINGER INGELHEIM INT·Filed 2015·Granted Jan 22, 2019·2 cites·15 claims
- 1375US10577336B2Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonistsBOEHRINGER INGELHEIM INT·Filed 2018·Granted Mar 3, 2020·1 cites·12 claims
- 1472US9012489B2Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicamentGIOVANNINI RICCARDO·Filed 2012·Granted Apr 21, 2015·2 cites·47 claims
- 1569US9308194B2Indanyloxyphenylcyclopropanecarboxylic acidsBOEHRINGER INGELHEIM INT·Filed 2014·Granted Apr 12, 2016·1 cites·13 claims
- 1663US2021221824A1Heterocyclic compounds as delta-5 desaturase inhibitors and methods of useAMGEN INC·Filed 2021·Application pending·0 cites
- 1762US11512097B2Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of useAMGEN INC·Filed 2020·Granted Nov 29, 2022·0 cites·38 claims
- 1855US2024108737A1Anti-infective bicyclic peptide ligandsBICYCLETX LTD·Filed 2022·Application pending·0 cites
- 1952US12473289B2Heterocyclic compounds as delta-5 desaturase inhibitors and methods of useAMGEN INC·Filed 2020·Granted Nov 18, 2025·0 cites·10 claims
- 2051US12091399B2Phenyltetrazole derivatives as plasma kallikrein inhibitorsBOEHRINGER INGELHEIM INT·Filed 2019·Granted Sep 17, 2024·0 cites·14 claims
- 2148US2025325672A1Anti-infective bicyclic peptide ligandsBICYCLE TX LTD·Filed 2022·Application pending·0 cites
- 2248US2024083944A1Anti-infective bicyclic peptide ligandsBICYCLE TX LTD·Filed 2022·Application pending·0 cites
- 2339US8648118B2Bicyclic ring system substituted amide functionalised phenols as medicamentsGIOVANNINI RICCARDO·Filed 2011·Granted Feb 11, 2014·0 cites·11 claims
- 2439US8648070B2Bicyclic ring system substituted sulfonamide functionalised phenols as medicamentsGIOVANNINI RICCARDO·Filed 2011·Granted Feb 11, 2014·0 cites·6 claims
- 2538US2009203737A1Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic ReceptorsGAGLIARDI STEFANIA·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →